BiotechTube

Riociguat + Placebo

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Scleroderma

Conditions

Scleroderma, Digital Ulcers

Trial Timeline

Sep 1, 2016 → Jul 24, 2018

NCT ID
NCT02915835

About Riociguat + Placebo

Riociguat + Placebo is a phase 2 stage product being developed by Bayer for Scleroderma. The current trial status is completed. This product is registered under clinical trial identifier NCT02915835. Target conditions include Scleroderma, Digital Ulcers.

Hype Score Breakdown

Clinical
12
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02915835Phase 2Completed

Competing Products

15 competing products in Scleroderma

See all competitors
ProductCompanyStageHype Score
IVA337 + PlaceboInventivaPhase 2
29
Cuprimine (penicillamine)MerckPre-clinical
26
rapcabtagene autoleucel + rituximabNovartisPhase 2
42
STI571NovartisPhase 2
35
Imatinib mesylateNovartisPhase 2
27
imatinib mesylateNovartisPhase 2
35
Mycophenolate mofetilRochePre-clinical
26
Mycophenolate mofetil + Cyclophosphamide + PlaceboRochePhase 2
35
Fludarabine + Cyclophosphamide + ThymoglobulinAmgenPhase 1
21
BMS-986020Bristol Myers SquibbPhase 2
27
dasatinibBristol Myers SquibbPhase 1/2
32
Abatacept + PlaceboBristol Myers SquibbPhase 1/2
32
AVID200Bristol Myers SquibbPhase 1
29
RilonaceptRegeneron PharmaceuticalsPhase 1/2
32
Riociguat (Adempas, BAY63-2521) + PlaceboBayerPhase 2
32